georgejjl Sunday, 10/20/19 03:43:55 PM Re: None Post # of 224518 Quote:LB19 - Novel analytics framework for augmenting single-arm Phase 2a open label trials with Real-World external control data: Application to the Blarcamesine (ANAVEX®2-73) study in Alzheimer’s disease matched with propensity corrected patients from Alzheimer’s Disease Neuroimaging Initiative (ADNI) exploring treatment effect on cognition at Interim two-year (104-Week) timepoint Mohammad Afshar (1), Coralie Williams (1), Nanthara Sritharan (1), Frederic Parmentier (1), Federico Goodsaid (2), Christopher Missling (3) (1) Ariana Pharma, France, (2) Regulatory Pathfinders, United States, (3) Anavex, United States Quote:P90: Gut Microbiota and Response to Blarcamesine (ANAVEX2- 73) in Alzheimer’s Disease Patients: Abundance of Lachnospiraceae and Enterobacteriaceae Families as Potential Biomarker of Response from a 2-Year Study Interim Clinical Data Analysis using KEM Artific Mohammad AFSHAR (1), Coralie WILLIAMS (1), Frederic PARMENTIER (1), Adrien ETCHETO (1), Christopher MISSLING (2) - (1)Ariana Pharma, France, (2)Anavex, United States Quote:P99: Levels of gut microbiota potentially regulated through anti-inflammatory effect identified as associated to response to Blarcamesine (ANAVEX2-73) in Alzheimer’s disease patients in 2-year Interim clinical data using KEM Artificial Intelligence analysis Mohammad AFSHAR (1), Coralie WILLIAMS (1), Frederic PARMENTIER (1), Adrien ETCHETO (1), Christopher MISSLING (2) - (1)Ariana Pharma, France, (2)ANAVEX, United States https://www.ctad-alzheimer.com/theme-4-clinical-trials-biomarkers Good luck and GOD bless,